The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2019 | With new treatment options in myeloma, is auto-SCT still necessary?
Inger Nijhof, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses whether there is still a need to perform autologous stem cell transplantations (auto-SCT) for patient with multiple myeloma. Dr Nijhof argues that there is not yet enough data from the clinical studies, especially surrounding overall survival rates, so we cannot be too quick to disregard the importance of auto-SCT. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
